Section Arrow
RYTM.NASDAQ
- Rhythm Pharmaceuticals
Quotes are at least 15-min delayed:2024/10/31 20:44 EDT
Last
 47.68
-1.86 (-3.75%)
Day High 
49.965 
Prev. Close
49.54 
1-M High
52.74 
Volume 
302.73K 
Bid
47.67
Ask
50.18
Day Low
47.61 
Open
49.42 
1-M Low
46.8 
Market Cap 
3.03B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 49.7 
20-SMA 49.45 
50-SMA 49.52 
52-W High 55.64 
52-W Low 23.83 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.35/-2.92
Enterprise Value
3.03B
Balance Sheet
Book Value Per Share
0.64
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
77.43M
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed:2024/10/31 20:44 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.